Skip to main content

Advertisement

Log in

Reduced-antigen-content-diphtheria-tetanus-acellular-pertussis and inactivated polio vaccine as a booster for adolescents 10 to 14 years of age

  • Original Paper
  • Published:
European Journal of Pediatrics Aims and scope Submit manuscript

Abstract

High rates of pertussis disease in adolescents suggest that additional boosting against pertussis would be beneficial. A combined acellular-pertussis-containing booster vaccine (dTpa-IPV; Boostrix™ Polio, n =440) was compared to separately administered dTpa (Boostrix™) and inactivated polio virus (IPV; Imovax Polio®, n =219), and to DTPa-IPV (Infanrix™ IPV, n =111) vaccine in a partially blind, randomised controlled trial in 10–14 year olds. One month after vaccination, seroprotection/seropositivity rates for all antigens were similar for all groups. Although pertussis and diphtheria antibody geometric mean antibody concentrations were higher after DTPa-IPV, all subjects had protective antibodies against diphtheria, tetanus and polio, and at least 97% had a vaccine response to pertussis antigens. Reactogenicity of dTpa-IPV was comparable to dTpa + IPV, but dTpa-IPV was generally better tolerated than DTPa-IPV. Conclusion:The combined reduced-antigen-content-diphtheria-tetanus-acellular-pertussis and IPV vaccine is immunogenic and well tolerated when administered to adolescents and could be used to improve the control of pertussis disease in this age group.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

CI :

confidence interval

DTPa :

diphtheria, tetanus and acellular pertussis vaccine

DTPw :

diphtheria, tetanus and whole-cell pertussis vaccine

dTpa-IPV :

dTpa-IPV reduced-antigen-content-diphtheria-tetanus-acellular-pertussis and IPV vaccine

GMC :

geometric mean antibody concentration

IPV :

inactivated polio virus

dTpa :

reduced-antigen-content-diphtheria-tetanus and acellular pertussis vaccine

References

  1. Aoyama T, Harashima M, Nishimura K, Saito Y (1995) Outbreak of pertussis in highly immunized adolescents and its secondary spread to their families. Acta Pediatr Japn 37: 321–324

    Google Scholar 

  2. Bonmarin I, Laurent E, Guiso N, Levy-Bruhl D, Renacoq (2003) Surveillance de la coqueluche à l’hopital en 2001. Bulletin Epidémiologique Hebdomadaire 44: 213–214

  3. Bulletin Epidémiologique Hebdomadaire (2003) Calendrier vaccinal 2003 Avis du Conseil supérieur d’hygiène publique de France 06: 33–37

  4. Cattaneo L, Reed G, Haase D, Wills M, Edwards K (1996) The seroepidemiology of Bordetella pertussis infections: a study of persons ages 1–65 years. J Infect Dis 173: 1256–1259

    Google Scholar 

  5. Campins-Marti M, Cheng HK, Forsyth K, Guiso N, Halperin S, Huang L-M, Mertsola J, Oselka G, Ward J, Wirsing von König CH, Zepp F (2002) Recommendations are needed for adolescent and adult pertussis immunisation: rationale and strategies for consideration. Vaccine 20: 641–646

    Google Scholar 

  6. Centers for Disease Control and Prevention (2002) Pertussis—United States, 1997–2000. MMWR 51: 73–76

    Google Scholar 

  7. Dagan R, Igbaria K, Piglansky L, Melamed R, Willems P, Grossi A, Kaufhold A (1997) Safety and immunogenicity of a combined pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus and Haemophilus influenzae type b-tetanus conjugate vaccine in infants, compared with a whole cell pertussis pentavalent vaccine. Pediatr Infect Dis J 16: 1113–1121

    Google Scholar 

  8. Gil A, Oyagüez I, Carrasco P, González A (2001) Hospital admissions for pertussis in Spain, 1995–1998. Vaccine 19: 4791–4794

    Google Scholar 

  9. Grimprel E, Baron S, Levy-Bruhl D, Garnier JM, N’jamkepo E, Guiso N, Bégué P (1999) Influence of vaccination coverage on pertussis transmission in France. Lancet 354: 1699–1770

    Google Scholar 

  10. Gylca R, Gylca V, Benes O, Melnic A, Chicu V, Weisbecker C, Willems P, Kaufhold A (2000) A new DTPa-HBV-IPV vaccine co-administered with Hib, compared to a commercially available DTPw-IPV/Hib vaccine co-administered with HBV, given at 6, 10 and 14 weeks following HBV at birth. Vaccine 19: 825–833

    Google Scholar 

  11. He Q, Viljanen M, Arvilommi H, Aittanen B, Mertsola J (1998) Whooping cough caused by Bordetella pertussis and Bordetella parapertussis in an immunized population. JAMA 280: 635–637

    Google Scholar 

  12. Izurieta H, Kenyon T, Strebel P, Baughman A, Shulman S, Wharton M (1996) Risk factors for pertussis in young infants during an outbreak in Chicago in 1993. Clin Infect Dis 22: 503–507

    Google Scholar 

  13. Lin M, Roche P, Spencer J, Milton A, Wright P, Witteveen D, Leader R, Merianos A, Bunn C, Gidding H, Kaldor J, Kirk M, Hall R, Della-Porta T (2002) Australia’s notifiable disease status, 2000: annual report of the national notifiable diseases surveillance system. Commun Dis Intell 26: 118–203

    Google Scholar 

  14. McIntyre P, Gidding H, Gilmour R, Lawrence G, Hull B, Horby P, Wang H, Andrews R, Burgess M (2002) Vaccine preventable diseases and vaccination coverage in Australia, 1999 to 2000. Commun Dis Intell [Suppl I-XI]: 1–111

  15. Mertsola J (2001) Has pertussis been tamed? Duodecim 117: 1101–1108

    Google Scholar 

  16. Morris A, Elliott E, McIntyre P, Massie J, Ridley G, McEniery J, Knight G and Contributors to the Australian Paediatric Surveillance Unit (APSU) (2002) Hospitalized pertussis in infancy. J Pediatr Child Health 38: A2

    Google Scholar 

  17. Nennig ME, Shinefield H, Edwards K, Black S, Fireman B (1996) Prevalence and incidence of adult pertussis in an urban population. JAMA 275: 1672–1674

    Google Scholar 

  18. Pichichero M, Deloria M, Rennels M, Anderson E, Edwards K, Decker M, Englund J, Steinhoff M, Deforest A, Meade B (1997) A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given a fourth dose in 15- to 20-month-old children. Pediatrics 100: 772–788

    Google Scholar 

  19. Schmitt HJ, Schuind A, Knuf M, Beutel K, Schulte-Wissermann H, Gahr M, Schult R, Folkens J, Rauh W, Bogaerts H, Bock HL, Clemens R (1996) Clinical experience of a tricomponent acellular pertussis vaccine combined with diphtheria and tetanus toxoids for primary vaccination in 22, 505 infants. J Pediatr 129: 695–701

    Google Scholar 

  20. Schmitt H, von König C, Neiss A, Bogaerts H, Bock HL, Schulte-Wissermann H, Gahr M, Schult R, Folkens JU, Rauh W, Clemens R (1996) Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA 275: 37–41

    Google Scholar 

  21. Skowronski D, De Serres G, MacDonald D, Wu W, Shaw C, Macnabb J, Champagne S, Patrick DM, Halperin SA (2002) The changing age and seasonal profile of pertussis in Canada. J Infect Dis 185: 1448–1453

    Google Scholar 

  22. Stojanov S, Liese J, Belohradsky B (2000) Hospitalization and complications in children under 2 years of age with Bordetella pertussis infection. Infection 28: 106–110

    Google Scholar 

  23. Vitek C, Pascual F, Baughman A, Murphy T (2003) Increase in deaths from pertussis among young infants in the United States in the 1990s. Pediatr Infect Dis J 22: 628–634

    Google Scholar 

  24. World Health Organization (2003) Vaccines, immunization and biologicals: pertussis vaccine (WHO-Vaccines, immunization and biologicals web site)http://www.who.int/vaccines/en/pertussis.shtml

  25. Zepp F, Cheuvart B, Wolter J (2003) Anti-diphtheria antibodies should persist until adolescence after a reduced-antigen diphtheria, tetanus and acellular pertussis vaccine (dTpa) in pre-school-aged children (abstract). 21st Annual Meeting of the European Society for Pediatric Infectious Diseases, Taormina Sicily, April 9-11

Download references

Acknowledgements

This study was supported by GlaxoSmithKline Biologicals, Rixensart, Belgium.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Rodrigo Vergara.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vergara, R., Tregnaghi, M., Ussher, J. et al. Reduced-antigen-content-diphtheria-tetanus-acellular-pertussis and inactivated polio vaccine as a booster for adolescents 10 to 14 years of age. Eur J Pediatr 164, 377–382 (2005). https://doi.org/10.1007/s00431-005-1650-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00431-005-1650-y

Keywords

Navigation